Meanwhile, MG132, as a proteasome inhibitor, reversed the inhibition of p53 expression by mir-26b in HCC cells under the action of adriamycin, which further confirmed that the down-regulation of p53 was achieved through proteasome-dependent degradation via p53 ubiquitination [130]. The gene discussed is TP53; the disease is hepatocellular carcinoma.